Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marshall Urist | $1,323,000 | $0 | $0 | $0 | $0 | $0 | $0 | $1,323,000 |
| Executive Vice President, Research & Investments | ||||||||
| George Lloyd | 1,323,000 | 0 | 0 | 0 | 0 | 0 | 0 | 1,323,000 |
| Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | ||||||||
| Christopher Hite | 1,323,000 | 0 | 0 | 0 | 0 | 0 | 0 | 1,323,000 |
| Executive Vice President & Vice Chairman | ||||||||
| Terrance Coyne | 1,323,000 | 0 | 0 | 0 | 0 | 0 | 0 | 1,323,000 |
| Executive Vice President & Chief Financial Officer | ||||||||
| Pablo Legorreta | 937,500 | 0 | 0 | 0 | 0 | 0 | 0 | 937,500 |
| Chairman and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marshall Urist | $1,323,000 | — | — | — |
| George Lloyd | 1,323,000 | — | — | — |
| Christopher Hite | 1,323,000 | — | — | — |
| Terrance Coyne | 1,323,000 | — | — | — |
| Pablo Legorreta | 937,500 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Pablo Legorreta | RSU | 11,798,458 | — | $455,892,417 |
| George Lloyd | RSU | 1,731,485 | — | 66,904,580 |
| Terrance Coyne | RSU | 1,610,300 | — | 62,221,992 |
| Marshall Urist | RSU | 1,212,135 | — | 46,836,896 |
| Christopher Hite | RSU | 1,108,137 | — | 42,818,414 |
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 476,044,602 | 11,067,486 | 747,086 | 97.73% | Passed |
| 2025 | 2025-05-12 | 403,157,465 | 36,842,162 | 750,557 | 91.63% | Passed |
| 2024 | 2024-06-06 | 448,091,225 | 37,716,521 | 218,819 | 92.24% | Passed |
| 2023 | 2023-06-22 | 483,910,458 | 28,152,706 | 233,765 | 94.5% | Passed |
| 2022 | 2022-06-23 | 480,577,839 | 21,850,442 | 140,001 | 95.65% | Passed |
| 2021 | 2021-06-24 | 455,808,359 | 47,703,018 | 1,558,689 | 90.53% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 97.73%a |
| 2025 | 2025-05-12 | 91.63%b |
| 2024 | 2024-06-06 | 92.24%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 4 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $349,893 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Vlad Coric, M.DIndependent · Compensation · Newly elected | $109,615 | $352,384 | — | — | $1 | $462,000 |
| Gregory NordenIndependent · Audit (Chair) · Nominating and Corporate Governance Committee | 150,000 | 249,891 | — | — | 90 | 399,981 |
| Ted Love, M.DIndependent · Nominating and Corporate Governance (Chair) | 150,000 | 249,891 | — | — | 90 | 399,981 |
| Catherine EngelbertIndependent · Audit | 150,000 | 249,891 | — | — | 90 | 399,981 |
| Errol De Souza, Ph.DIndependent · Not standing for re-election | 150,000 | 249,891 | — | — | 90 | 399,981 |
| Bonnie Bassler, Ph.DIndependent · Compensation | 150,000 | 249,891 | — | — | 90 | 399,981 |
| David HodgsonIndependent · Audit · Management Development and Compensation Committee (Chair) | 150,000 | 249,891 | — | — | 90 | 399,981 |
| Elizabeth WeathermanIndependent · Compensation · Newly elected | 68,071 | 314,934 | — | — | — | 383,005 |
| Carole Ho, M.DIndependent · Nominating and Corporate Governance · Newly elected | 68,071 | 314,934 | — | — | — | 383,005 |
| Henry FernandezIndependent · Departed during FY | 92,935 | 249,891 | — | — | — | 342,826 |
| Pablo LegorretaEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $150,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | $750,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,238,692 |
| Equity awards (grant-date value) | $2,731,489 |
| All other compensation | $541 |
| Total cost of the board | $3,970,722 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Royalty Pharma names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Royalty Pharma.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Blackstone | 2025 | Stephen Schwarzman | $350,000 | $0 | $0 | $0 | $125,641,824 |
| 2 | KKR | 2025 | Joseph Bae | 300,000 | 0 | 0 | 0 | 84,270,205 |
| 3 | Ares | 2025 | Michael Arougheti | 0 | 49,520,000 | 0 | 0 | 68,279,532 |
| 4 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 5 | AbbVie | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 6 | Incyte | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 7 | TPG | 2025 | Jon Winkelried | 500,000 | 13,607,777 | 0 | 0 | 29,897,761 |
| 8 | Gilead | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 9 | Pfizer | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 10 | Amgen | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 11 | Biogen | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 12 | BioMarin | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 13 | Bristol-Myers Squibb | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 14 | Vertex Pharmaceuticals | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 15 | Merck & Co. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 16 | Regeneron | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
| 17 | Carlyle | 2025 | Harvey Schwartz | 1,000,000 | — | — | 6,000,000 | 7,149,859 |
| 18 | Royalty Pharma | 2025 | Pablo Legorreta | 937,500 | 0 | 0 | 0 | 937,500 |
| 19 | Apollo | 2025 | Marc Rowan | 100,000 | 0 | 0 | 0 | 913,367 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Royalty Pharma | not disclosed | not disclosed | not disclosed | not disclosed |
| AbbVie | not disclosed | PSU 40 · RSU 40 · Options 20 | Yes — Relative TSR | Semler Brossy |
| Amgen | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Apollo | 94% | RSU 100 | not disclosed | Semler Brossy Consulting Group, LLC |
| Ares | not disclosed | RSU 100 | not disclosed | Korn Ferry |
| Biogen | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Blackstone | not disclosed | not disclosed | not disclosed | not disclosed |
| Bristol-Myers Squibb | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Carlyle | 200% | not disclosed | No | Pay Governance |
| Gilead | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Incyte | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Johnson & Johnson | not disclosed | not disclosed | not disclosed | Semler Brossy Consulting Group |
| KKR | not disclosed | not disclosed | not disclosed | not disclosed |
| Merck & Co. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Pfizer | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
| Regeneron | 155% | Options 60 · RSA 40 | not disclosed | Pay Governance LLC |
| TPG | not disclosed | not disclosed | No | Semler Brossy |
| Vertex Pharmaceuticals | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Marshall Urist | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Summary Compensation Table” · page 59. As printed: 1,323,000. Filing ↗machine: r14 · c19 · span 1460013–1460022 |
| 2 | Section 01, George Lloyd | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Summary Compensation Table” · page 59. As printed: 1,323,000. Filing ↗machine: r11 · c19 · span 1449155–1449164 |
| 3 | Section 01, Christopher Hite | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Summary Compensation Table” · page 59. As printed: 1,323,000. Filing ↗machine: r8 · c19 · span 1439390–1439399 |
| 4 | Section 01, Terrance Coyne | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Summary Compensation Table” · page 59. As printed: 1,323,000. Filing ↗machine: r5 · c19 · span 1428569–1428578 |
| 5 | Section 01, Pablo Legorreta | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Summary Compensation Table” · page 59. As printed: 937,500. Filing ↗machine: r2 · c19 · span 1425057–1425064 |
| 6 | Section 07, pay ratio | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “CEO Pay Ratio”. As printed: 4 : 1. Filing ↗ |
| 7 | Section 08, Vlad Coric, M.D | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 462,000. Filing ↗machine: span 946363–946370 |
| 8 | Section 08, Gregory Norden | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 960479–960486 |
| 9 | Section 08, Ted Love, M.D | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 958598–958605 |
| 10 | Section 08, Catherine Engelbert | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 950421–950428 |
| 11 | Section 08, Errol De Souza, Ph.D | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 948265–948272 |
| 12 | Section 08, Bonnie Bassler, Ph.D | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 944196–944203 |
| 13 | Section 08, David Hodgson | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 399,981. Filing ↗machine: span 956447–956454 |
| 14 | Section 08, Elizabeth Weatherman | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 383,005. Filing ↗machine: span 962596–962603 |
| 15 | Section 08, Carole Ho, M.D | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 383,005. Filing ↗machine: span 954567–954574 |
| 16 | Section 08, Henry Fernandez | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 342,826. Filing ↗machine: span 952359–952366 |
| 17 | Section 08, Pablo Legorreta | DEF 14A | 2026-04-10 | 0001140361-26-014239 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001193125-26-257432 | Item 5.07 · say-on-pay result. As reported: 97.73% (votes for as printed: 476,044,602). Filing ↗ |
| 19 | Section 06, 2025 vote | Form 8-K | 2025-05-12 | 0001193125-25-117771 | Item 5.07 · say-on-pay result. As reported: 91.63% (votes for as printed: 403,157,465). Filing ↗ |
| 20 | Section 06, 2024 vote | Form 8-K | 2024-06-06 | 0001193125-24-156183 | Item 5.07 · say-on-pay result. As reported: 92.24% (votes for as printed: 448,091,225). Filing ↗ |
| 21 | Section 09b board cost (computed) | Computed | — | computed | Cash 1,238,692 + equity 2,731,489 + all other 541 = 3,970,722, summed across the director compensation table rows.machine: formula: Σ = 3,970,722 |
| 22 | Blackstone, Section 10b CEO total | 10-K | 2026-02-27 | 0001193125-26-082531 | CEO total compensation as printed in Blackstone's own proxy. As printed: 125,641,824. Filing ↗machine: span 8525664–8525675 |
| 23 | KKR, Section 10b CEO total | 10-K | 2026-02-27 | 0001404912-26-000007 | CEO total compensation as printed in KKR's own proxy. As printed: 84,270,205. Filing ↗machine: t246 · r10 · c12 · span 18528931–18528941 |
| 24 | Ares, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026286 | CEO total compensation as printed in Ares's own proxy. As printed: 68,279,532. Filing ↗machine: t10 · r3 · c16 · span 335528–335538 |
| 25 | Johnson & Johnson, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000200406-26-000063 | CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246 |
| 26 | AbbVie, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001104659-26-033387 | CEO total compensation as printed in AbbVie's own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093 |
| 27 | Incyte, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 28 | TPG, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-166834 | CEO total compensation as printed in TPG's own proxy. As printed: 29,897,761. Filing ↗machine: r5 · c23 · span 437878–437888 |
| 29 | Gilead, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 30 | Pfizer, Section 10b CEO total | DEF 14A | 2026-03-12 | 0000078003-26-000033 | CEO total compensation as printed in Pfizer's own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835 |
| 31 | Amgen, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145588 | CEO total compensation as printed in Amgen's own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166 |
| 32 | Biogen, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen's own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 33 | BioMarin, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 34 | Bristol-Myers Squibb, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 35 | Vertex Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 36 | Merck & Co., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 37 | Regeneron, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 38 | Carlyle, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001527166-26-000017 | CEO total compensation as printed in Carlyle's own proxy. As printed: 7,149,859. Filing ↗machine: span 1925524–1925533 |
| 39 | Royalty Pharma (subject), Section 10b CEO total | DEF 14A | 2026-04-10 | 0001140361-26-014239 | CEO total compensation as printed in Royalty Pharma's own proxy. As printed: 937,500. Filing ↗machine: r2 · c19 · span 1425057–1425064 |
| 40 | Apollo, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177321 | CEO total compensation as printed in Apollo's own proxy. As printed: 913,367. Filing ↗machine: r2 · c21 · span 538543–538550 |
| 41 | Section 10a, Vertex Pharmaceuticals reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 42 | Section 10a, Carlyle reciprocity | DEF 14A | — | 0001527166-26-000017 | Carlyle's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 43 | Section 10a, Pfizer reciprocity | DEF 14A | — | 0000078003-26-000033 | Pfizer's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 44 | Section 10a, Merck & Co. reciprocity | DEF 14A | — | 0001193125-26-147704 | Merck & Co.'s most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 45 | Section 10a, Regeneron reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 46 | Section 10a, BioMarin reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 47 | Section 10a, Gilead reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 48 | Section 10a, Johnson & Johnson reciprocity | DEF 14A | — | 0000200406-26-000063 | Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 49 | Section 10a, AbbVie reciprocity | DEF 14A | — | 0001104659-26-033387 | AbbVie's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 50 | Section 10a, Amgen reciprocity | DEF 14A | — | 0001193125-26-145588 | Amgen's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 51 | Section 10a, Bristol-Myers Squibb reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |
| 52 | Section 10a, Apollo reciprocity | DEF 14A | — | 0001193125-26-177321 | Apollo's most recent proxy was read; its disclosed peer group does not include Royalty Pharma. Filing ↗ |